DexCom’s Q2 earnings smashed expectations with $1.31 billion in revenue, up 13% year-over-year, and they’ve boosted their full-year forecast to $5.22 billion. Profit per share also exceeded predictions, highlighting strong operational efficiency. Their CGM systems are driving global demand, especially among type two diabetes patients not on insulin, thanks to a new 15-day G7 version and expanded manufacturing in Ireland. CEO praise for solid execution includes new product launches, market share gains, and international growth fueled by improved insurance coverage. The company’s acquisition of Nutrisense signals a push into personalized nutrition using CGM data, while ongoing efforts to secure broader Medicare reimbursement and develop next-gen sensors position DexCom for sustained growth and deeper patient impact.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
